CytomX Therapeutics (CTMX) Provides Business Update and Outlines 2023 Goals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
January 5, 2023 4:05 PM EST- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to determine next steps for program in 2023 -
- CytomX and Moderna announce today, separately, a strategic collaboration to research and develop messenger RNA-based conditionally activated therapeutics -
- Broad pipeline progress anticipated in 2023 including continued advancement of clinical stage partnered programs, filing of two INDs for next generation wholly owned programs and broadening of R&D activities... More
